Comorbidities are common in children with epilepsy, with nearly half of the patients having
at least one comorbidity. Attention deficit hyperactivity disorder (ADHD) is a psychiatric …

The current therapy for depression is less than ideal with remission rates of only 25–35%
and a slow onset of action with other associated side effects. The persistence of anhedonia …

In idiopathic Parkinson disease and atypical parkinsonian disorders, central dopaminergic
and overall brain functional activity are altered to different degrees, causing difficulties in …

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder
characterized by symptoms of inattention, hyperactivity, and impulsivity associated with …

Although first-line antidepressants offer therapeutic benefit, about 35% of depressed
patients are not adequately treated, creating a large unmet medical need. These medicines …

Effective treatment with antidepressants is currently limited by factors that affect treatment
compliance, including delay in onset of therapeutic effects and intolerable side-effects …

Many patients with major depressive disorder (MDD) only partially respond, and some have
no clinically meaningful response, to current widely used antidepressant drugs. Due to the …

Inhibitors of dopamine transporters (DAT), norepinephrine transporters (NET) and serotonin
transporters (SERT) are effective treatments for neuropsychiatric diseases. Dasotraline [(1R …

SMe1EC2M3 is a pyridoindole derivative related to the neuroleptic drug carbidine. Based on
the structural similarities of SMe1EC2M3 and known serotonin (5-HT), norepinephrine, and …

Abstract Background and Objectives Dasotraline is a novel inhibitor of dopamine and
norepinephrine reuptake currently being investigated in clinical studies for the treatment of …